Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R 英文参考文献.docVIP

下载本文档

3
0
约3.41万字
约 6页
2017-05-11 发布于上海
举报
版权申诉

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R 英文参考文献.doc

1、本文档共6页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R 英文参考文献

Open access, freely available online Correspondence Misleading Information on the Properties of Vitamin C Steve Hickey (radicalascorbate@) Manchester Metropolitan University Manchester, United Kingdom Steve Hickey, Hilary Roberts Hilary Roberts The Cochrane review by Douglas et al. [1], which is referenced in the Best Practice article by Douglas and Hemil? [2], covers 60 years of research into vitamin C and the common cold. However, the review omits pharmacokinetic data that invalidate the conclusion that vitamin C is ineffective. This conclusion is not derivable from the data presented. The dual-phase pharmacokinetics of vitamin C are described by the dynamic ?ow model [3,4]. Low gram-level intakes of ascorbate, leading to blood plasma levels below 70 μM/l, have a half-life of 8–40 days. Higher gram-level intakes have a plasma half-life of 30 minutes [3]. A large oral dose raises blood plasma levels brie?y: they reach a peak after two to three hours, before decaying back to baseline. Frequent repeated doses allow sustained high plasma levels of about 250 μM/l [4,5]. Douglas and Hemil? reviewed intakes that transiently raise plasma ascorbate levels above 70 μM/l. A single dose does not raise the median level [6,7]. Daily supplements would, thus, not increase disease resistance to any great degree [3,4]. Single or double doses daily will not increase background plasma levels, regardless of the magnitude of the dose [6,7]. Since plasma ascorbate is at background level for the majority of the day, effects will be minimal. Manchester, United Kingdom References 1. Douglas RM, Hemil? H, D’Souza R, Chalker EB, Treacy B (2004) Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 4: CD000980.pub2. 2. 3. 4. 5. Douglas RM, Hemil? H (2005) Vitamin C for preventing and treating the common cold. PLoS Med 2: e168. DOI: 10.1371/journal.pmed.0020168 Hickey S, Roberts HJ (2004) Ascorbate: The science of vitamin C. Napa (California): Lulu Press. 264